Durability of Response in Certolizumab Pegol-Treated Patients Over 48 Weeks in CIMPASI-1 & 2 Trials
Author Type(s)
Faculty
Document Type
Abstract
Publication Date
6-2018
Journal Title
Acta Dermato-Venereologica
Department
Dermatology
Recommended Citation
Reich, K., Blauvelt, A., Thaci, D., Leonardi, C., Poulin, Y., Peterson, L., Arendt, C., & Gottlieb, A. B. (2018). Durability of Response in Certolizumab Pegol-Treated Patients Over 48 Weeks in CIMPASI-1 & 2 Trials. Acta Dermato-Venereologica, 98 (Suppl. 219), 26. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/349
COinS
